Dr. Knobelman joined the Company on June 3, 2024 and oversees the finance, accounting, business development, investor relations and corporate strategy functions. Istisociclib (KB-0742), a CDK9 ...

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Kronos Worldwide (KRO) reports results for the quarter ended June 2025. While this widely-known consensus outlook is ...

Dallas, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Kronos Worldwide, Inc. (NYSE:KRO) today reported a net loss of $82.8 million, or $.72 per share, in the fourth quarter of 2025 compared to a net loss ...

SAN MATEO, Calif., and CAMBRIDGE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent ...